This technology is a formulation that uses soluble receptors for advanced glycation end products (sRAGE) to prevent neointimal hyperplasia and atherosclerosis.
Unmet Need: A targeted therapy for preventing accelerated atherosclerosis in diabetes
Diabetic patients often experience cardiovascular complications, including accelerated atherosclerosis. Current methods of counteracting this include using antibodies and other immune system modulators to inhibit neointimal hyperplasia. These treatments often yield suboptimal modifications to immune function, as they are not specific to the root cause of diabetic restenosis.
The Technology: A specific intervention for diabetic neointimal hyperplasia using sRAGE
This technology uses sRAGE to compete against the activity of RAGE and specifically prevent the accelerated formation of atherosclerotic tissue in diabetes. By targeting the RAGE pathway, this therapy minimizes off-target effects and can be administered locally through a stent or other device. As inhibitors of RAGE have been shown to prevent unwanted tissue growth after blood vessel injury, this technology may improve neointimal health and decrease the probably of developing atherosclerosis after cardiovascular procedures.
This technology has been shown to suppress neointimal formation in a rat model of diabetes.
Applications:
- Inhibition of unwanted tissue growth in blood vessels after injury
- Neointimal hyperplasia prevention
- Prevention of recurring stenosis in diabetic patients
- Reduction of complications after angioplasty and stenting
Advantages:
- Specific to the root causes of diabetic hyperplasia
- Non-toxic
- Fewer side effects than immune system modulators
- Effective for preventing neointimal formation
Lead Inventor:
Ann Marie Schmidt, M.D.
Patent Information:
Patent Status
Related Publications:
Wang K, Zhou Z, Zhang M, Fan L, Forudi F, Zhou X, Qu W, Lincoff AM, Schmidt AM, Topol EJ, Penn MS. “Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model” J Pharmacol Exp Ther. 2006 Apr; 317(1): 37-43.
Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM, Lincoff AM, Topol EJ. “Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury” Circulation. 2003 May 6; 107(17): 2238-2243.
Sakaguchi T, Yan SF, Yan SD, Belov D, Rong LL, Sousa M, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka Y. “Central role of RAGE-dependent neointimal expansion in arterial restenosis” J Clin Invest. 2003 Apr; 111(7): 959-972.
Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. “Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins” J Biol Chem. 1992 Jul 25; 267(21): 14998-15004.
Tech Ventures Reference: